Benzinga - by Lisa Levin, Benzinga Editor.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. (NYSE: PFE)
- Dividend Yield: 5.07%
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $42 to $40 on Aug. 2, 2023. This analyst has an accuracy rate of 65%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and slashed the price target from $50 to $44 on March 17, 2023. This analyst has an accuracy rate of 74%.
- Recent News: The European Commission has approved ViiV Healthcare's Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention. ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi as shareholders.
- Dividend Yield: 4.94%
- BMO Capital analyst Gary Nachman downgraded the stock from Outperform to Market Perform and cut the price target from $16 to $14 on Feb. 17, 2023. This analyst has an accuracy rate of 69%.
- Piper Sandler analyst David Amsellem upgraded the stock from Underweight to Neutral with a price target of $10 on Nov. 8, 2022. This analyst has an accuracy rate of 71%.
- Recent News: Viatris reported second-quarter sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the consensus of $3.89 billion.
- Dividend Yield: 4.01%
- Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $86 to $88 on Aug. 4, 2023. This analyst has an accuracy rate of 63%.
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $83 to $84 on Aug. 4, 2023. This analyst has an accuracy rate of 80%.
- Recent News: Gilead Sciences revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.